Cystic fibrosis is a genetic disease caused by mutation of the CFTR gene, which encodes a chloride and bicarbonate transporter in epithelial cells. Due to the vast range of geno- and phenotypes, it is difficult to find causative treatments; however, small-molecule therapeutics have been clinically approved in the last decade. Still, the search for novel therapeutics is ongoing, and thousands of compounds are being tested in different assays, often leaving their mechanism of action unknown. Here, we bring together a CFTR-specific compound database (CandActCFTR) and systems biology model (CFTR Lifecycle Map) to identify the targets of the most promising compounds. We use a dual inverse screening approach, where we employ target- and ligand-based methods to suggest targets of 309 active compounds in the database amongst 90 protein targets from the systems biology model. Overall, we identified 1038 potential target-compound pairings and were able to suggest targets for all 309 active compounds in the database.
- Vinhoven, L.
- Stanke, F.
- Hafkemeyer, S.
- Nietert, M. M.
Keywords
- Humans
- *Cystic Fibrosis/drug therapy/genetics/metabolism
- Cystic Fibrosis Transmembrane Conductance Regulator/genetics/metabolism
- Chlorides/metabolism
- Ligands
- Bicarbonates/metabolism
- Mutation
- Pharmaceutical Preparations
- cystic fibrosis
- docking
- ligand-based drug design
- target-based drug design/target identification
- virtual screening